(Voting Panel Chairman)
Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding Design Portfolio in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.
Having established the Healthcare group from a standstill at Northland Capital Partners (acquired by SP Angel in February 2019) Vadim now leads this franchise at SP Angel. Since 2015, when Vadim joined Northland, the group has worked on over 20 healthcare transactions in which over £140m of capital was raised. Prior to Northland, Vadim worked at DS&C plc, where he led the Research department and established a Healthcare franchise which achieved a top Hemscott ranking by number of clients. Vadim also worked in research and healthcare analysis roles in Montreal, Canada. Vadim holds a BSc in Microbiology and Immunology and a Master’s degree in Economics from McGill University.
Ailsa joined SVLS in November 2006 as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets-focused team. Previously, Ailsa worked at Baring Asset Management for two years as a Research Analyst, covering pharmaceutical and biotechnology stocks. Prior to this, Ailsa worked for Insight Investment/Rothschild Asset Management (merged in 2003) within the Global/US Investment team. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.
Anne Marieke has over 20 years’ experience as a Buyside Fund Manager and Analyst responsible for investing across the global healthcare sector. She joined Optimum from Amundi Asset Management, Europe’s largest asset manager and a top ten firm globally. She joined Amundi as Deputy Head of the Global Equity team in January 2014 and was responsible for setting up the team’s research platform. Prior to this, Anne Marieke was responsible for global healthcare at ING Investment Management, Credit Suisse Asset Management, Threadneedle Asset Management and Gulf International Bank. She also helped set up the European franchise for Cross Current Research LLC. Anne Marieke started her career as a Medical Sales Representative at Roche and 3M Pharmaceuticals in the Netherlands. She graduated in Biology with Medical Specialisation from the University of Utrecht. Anne Marieke recently qualified as an AoEC Executive Coach.
Christian joined Stifel in May 2016 as a Healthcare Analyst and has been covering the healthcare sector for the last 17 years. Prior to Stifel, Christian was Head of Healthcare Research at Edison Investment Research and previously held senior analyst and editorial roles at EvaluatePharma and EP Vantage. He was also a Marketing Analyst and Research Scientist at Zeneca Agrochemicals. Christian holds a BSc in Zoology from the University of Leeds and an MSc in Crop Protection from the University of Reading.
Nooman is the Managing Director of Life Sciences and Healthcare at Silicon Valley Bank’s UK branch. He leads a team supporting early, growth-stage and established multi-national businesses in all sectors of life sciences. Nooman is responsible for expanding the bank’s business across Europe. As part of an international team he helps clients with innovative financing solutions through the bank’s broad platform of investment and commercial banking, asset management and capital connections. He is a frequent panellist, writer and spokesperson for the industry and has also advised the UK Government. Nooman’s background in healthcare includes consulting, Government policy and equity investing as a VC and sovereign investor. He was educated at the University of London and graduated with an advanced degree in economics and an MBA, and completed his undergraduate studies in psychology.
Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to this, he was Chief Financial Officer of Silence Therapeutics plc. Max possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks.
Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Accountant with Arthur Andersen.
Dan is Content and Strategy Director at Design Portfolio. A specialist in content strategy and corporate communications, Dan helps companies to improve their investor communications and wider stakeholder engagement. He has worked with a wide variety of FTSE 350 and international blue-chip clients and has held events and workshops on a number of topics, including integrated reporting, building a value proposition, articulating the business model and improving corporate governance reporting. He holds a Certificate in IR and is a certified sustainability practitioner.
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 20 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies. Prior to Canaccord Genuity, Julie was a member of the No.1 Extel-rated Healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Life Sciences Research. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.
Ivo currently heads up the Public Equity team at HBM Partners. This company was founded in 2001, with the goal to invest in private and public emerging biopharma and other healthcare-related companies. HBM Partners manages and advises several investment companies and funds, the best-known of which is HBM Healthcare Investments. Ivo joined HBM Partners in 2003 as Investment Advisor for the Biotechnology and Pharma sector. Prior to that, Ivo worked as a Biotechnology Analyst at Bank Sarasin, and before that was Department Head at MDS Pharma Services, Switzerland. Ivo studied chemistry at the University of Groningen, the Netherlands, and was a visiting scholar at the Department of Biology at MIT in 1991. He obtained his PhD in Biology from the ETH in Zurich, Switzerland, in 1996. He has over 18 years’ experience in investment management and research, and is a CFA Charter Holder since 2004.
Gary is an experienced healthcare analyst, having worked in the City since early 2001. He joined Bryan, Garnier & Co in September 2017 as Managing Director, UK Healthcare Research. He has been responsible for research coverage of the Life Sciences sector, including companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has been involved with numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Zeus Capital, Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed R&D groups at a Canadian biotech company and before that he was a Postdoctoral Fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. He holds an MBA (University of Durham Business School) and a PhD in Immunology from the Faculty of Medicine, Monash University (Melbourne, Australia).
Mette is Managing Partner of Lundbeckfonden Ventures, an evergreen life science venture fund. Mette has more than 20 years of broad international experience within biotech and life science, covering business development and licensing, management, and financing. She was previously co-founder and CEO of 7TM Pharma. Prior to that she was part of the management team of NeuroSearch A/S responsible for business development and licensing and has, over the years, co-founded several biotech companies. She started her career as a Patent Agent. Mette has been appointed to numerous Board positions both in private and public companies. Mette graduated with a degree in Biology from the University of Copenhagen and also has an MBA.
Simon joined FTI from Evolution Securities, where he was the Research Analyst responsible for the biotech and small-cap healthcare sector. Prior to that Simon spent several years on the buy-side, including stints at Millennium Capital and Lehman Brothers as the Analyst on global healthcare investment portfolios. Before that he was again on the sell-side as the European Biotech Analyst at Bear Stearns. He began his City career at Williams de Broë, also as a Healthcare Analyst. Simon also has first-hand experience of the biotech industry, having worked as a scientist at Peptide Therapeutics (Acambis). By profession Simon is a chemist, obtaining his credentials at Imperial College London, Cambridge University and Stanford University. His current clients include Genmab, Hansa Biopharma, GW Pharma, Consort Medical, Verona Pharma and Reviral.
Victoria joined J.P. Morgan Asset Management in the European Research team covering the healthcare sector more than ten years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.
Chris has more than 15 years’ experience in strategic communications from across the healthcare sector and has worked with companies at all stages of development including for some of the world’s leading pharmaceutical and biotechnology companies. He has led communications strategies on multiple cross-border IPOs, private fundraisings and international M&A. His corporate communication experience includes extensive profile-raising campaigns to support companies’ business objectives and crisis communication.
Chris was formerly a Director in the Life Sciences team at Citigate Dewe Rogerson, where he worked from 2003 to 2015 and an Associate Director at former specialist bioscience communications consultancy HCC De Facto. He has degrees in Biological Sciences and Psychology, a background in Journalism and a PhD in Molecular Biology.
Stefan is a Director of Equity Research in the Healthcare and Life Sciences team at Numis, which is currently the No.1 Extel (2018) ranked team in the UK sector. The Numis team provides broad coverage of over 30 UK-listed mid and small-cap healthcare and life sciences companies and acts as broker or adviser to around 20 listed and private companies in the sector. Prior to joining Numis in January 2016, Stefan spent five years at Peel Hunt, where he helped build the team to achieve the No.1 Extel sector ranking for three years in a row between 2012–14. Stefan has 15 years of experience as an Equity Analyst and has helped to raise over £2bn for healthcare and life sciences companies. Prior to becoming an analyst, Stefan spent several years in strategy consulting. He has a PhD in Antibody Engineering from the University of Cambridge and is a CFA charterholder.
Anne has been Managing Partner of MC Services since 2011 and has over 20 years of experience in financial and strategic communications. She was responsible for setting up the MC Services office in Düsseldorf and building the team and operations there. Prior to that, she held senior management positions in international pharma and biotech companies. She headed the Investor Relations and Corporate Communications department of Evotec AG for ten years and was a member of the company’s Executive Committee. Previously, she was responsible for investor relations and corporate communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and NASDAQ, multiple M&A programmes and major financial transactions. Anne is a pharmacist and marketing expert by training. Her sector expertise includes Pharma and Life Sciences, with experience in all major indication areas.
Geraldine joined LSP in 2008. She became a Partner of the firm in 2010. Geraldine’s prime focus and responsibility within LSP is to invest in listed securities. Prior to joining LSP, she held the position of Senior Healthcare Analyst at Fortis Investment Banking. In that position, she researched a wide range of innovative life sciences companies, both in Europe and the US. Geraldine brings strong analytical and investment skills to the LSP team. Before joining the financial community, she worked within the Life Sciences industry for a number of years, gaining first-hand product development experience in a commercial setting. Prior to working in the industry, she lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a very strong scientific background, including a Bachelor’s degree in Biochemistry and Microbiology from University College Cork and a Master’s degree in Biotechnology from University College Galway. She also conducted post-graduate research, inter alia at the prestigious Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. In addition, Geraldine is also a graduate of the Dublin School of Business.
Nick is an experienced Non-executive Director and Chairman with a background as a successful corporate financier. He has considerable experience of businesses in the Healthcare, Medical, Biotechnology, Environmental and Technology sectors.
Nick is Chairman of Destiny Pharma plc, an anti-infectives drug developer. He is also chairman of SEHTA, one of the largest health technology networking organisations in the UK, and of Interactive Me, a person-centred care business. Nick is a part-time Director of Alcuris, an emerging Telecare and Telehealth business. Until 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Through Ipso Ventures he helped found Therakind, a developer of paediatric medicines.
Sachin is the co-founder and Fund Manager of Third Eye Healthcare Fund. Third Eye is an open ended long-biased long/short global healthcare investment fund. The Fund’s objective is to generate long-term returns for investors by investing in carefully selected publicly listed healthcare companies. The Fund’s performance should come primarily from long positions, with short positions providing protection in the event of market corrections. The Fund maintains up to 50% exposure to European Healthcare. Prior to incorporating Third Eye in 2016, Sachin worked as Director and Head of the Life Sciences team in the securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Healthcare and Life Sciences sector and won Extel and StarMine awards for stock picking. He has over fifteen years of experience in life sciences, with an exposure to both private (Venture Capital) as well as public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies.
Melanie is a Partner, Life Sciences, at Instinctif and she leads on financial communications within the Life Sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VC and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse, where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford.